These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 17116421)

  • 21. [Methodologic and organizational principles of selective screening for cervical, endometrial and ovarian carcinoma].
    Zalutskiĭ IV; Vishnevskaia EE; Kurian LM
    Vopr Onkol; 2006; 52(1):74-7. PubMed ID: 16715709
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Proteins' promise--progress and challenges in ovarian cancer proteomics.
    Koehn H; Oehler MK
    Menopause Int; 2007 Dec; 13(4):148-53. PubMed ID: 18088525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay.
    Bristow RE; Smith A; Zhang Z; Chan DW; Crutcher G; Fung ET; Munroe DG
    Gynecol Oncol; 2013 Feb; 128(2):252-9. PubMed ID: 23178277
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The value of CA125 and LDH assays in assisting diagnosis of epithelial ovarian carcinoma].
    Qie M; Peng Z; Cao Z; Tang Q; He B
    Hua Xi Yi Ke Da Xue Xue Bao; 1996 Sep; 27(3):310-3. PubMed ID: 9389070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Status of tumor markers in ovarian cancer screening.
    Bast RC
    J Clin Oncol; 2003 May; 21(10 Suppl):200s-205s. PubMed ID: 12743135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Value of positron emission tomography-CT imaging combined with continual detection of CA125 in serum for diagnosis of early asymptomatic recurrence of epithelial ovarian carcinoma].
    Sheng XG; Zhang XL; Fu Z; Li HQ; Li QS; Ma ZF; Li DP; Chen ZY
    Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):460-3. PubMed ID: 17961335
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is it possible to have organized screening for ovarian cancer?].
    Navone R; Montanari G
    Pathologica; 2003 Apr; 95(2):67-70. PubMed ID: 12768874
    [No Abstract]   [Full Text] [Related]  

  • 28. Screening for ovarian cancer in the general population.
    Chu CS; Rubin SC
    Best Pract Res Clin Obstet Gynaecol; 2006 Apr; 20(2):307-20. PubMed ID: 16364690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Diagnostic value of combining detection of human epididymis protein 4 and CA125 in patients with malignant ovarian carcinoma].
    Wang MJ; Qi J; Wang H; Li XX; Wei BJ; Fu C; Gao J; Han BB
    Zhonghua Zhong Liu Za Zhi; 2011 Jul; 33(7):540-3. PubMed ID: 22093635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Factors influencing serum CA125II levels in healthy postmenopausal women.
    Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
    Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evolution of screening for epithelial ovarian carcinoma: the quest for early diagnosis.
    Look KY
    Semin Surg Oncol; 1994; 10(4):261-7. PubMed ID: 8091068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses.
    Lenhard M; Stieber P; Hertlein L; Kirschenhofer A; Fürst S; Mayr D; Nagel D; Hofmann K; Krocker K; Burges A
    Clin Chem Lab Med; 2011 Sep; 49(12):2081-8. PubMed ID: 21923475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for ovarian cancer: a pilot randomised controlled trial.
    Jacobs IJ; Skates SJ; MacDonald N; Menon U; Rosenthal AN; Davies AP; Woolas R; Jeyarajah AR; Sibley K; Lowe DG; Oram DH
    Lancet; 1999 Apr; 353(9160):1207-10. PubMed ID: 10217079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative analysis of CA125, tissue polypeptide specific antigen, and soluble interleukin-2 receptor alpha levels in sera, cyst, and ascitic fluids from patients with ovarian carcinoma.
    Sedlaczek P; Frydecka I; Gabryś M; Van Dalen A; Einarsson R; Harłozińska A
    Cancer; 2002 Nov; 95(9):1886-93. PubMed ID: 12404282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Three-dimensional ultrasonography and power Doppler in ovarian cancer screening of asymptomatic peri- and postmenopausal women.
    Kurjak A; Prka M; Arenas JM; Sparac V; Merce LT; Corusic A; Ivancic-Kosuta M
    Croat Med J; 2005 Oct; 46(5):757-64. PubMed ID: 16158468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The current status of ultrasound and color Doppler imaging in screening for ovarian cancer.
    Karlan BY; Platt LD
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S28-33. PubMed ID: 7835806
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress and challenges in screening for early detection of ovarian cancer.
    Jacobs IJ; Menon U
    Mol Cell Proteomics; 2004 Apr; 3(4):355-66. PubMed ID: 14764655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
    Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
    Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Epidemiology and screening of ovarian cancer.
    Tortolero-Luna G; Mitchell MF; Rhodes-Morris HE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):1-23. PubMed ID: 8015758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.